FORT WORTH, Texas, Jan. 30, 2024 CorVel Corporation announced the results for the quarter ended December 31, 2023. Revenues for the quarter were $202 million, an increase from $179 million in.
Experts discuss the ramifications of red blood cell transfusion shortages on myelofibrosis patient management and delve into the scarcity's effects, patient prioritization, and the struggle for consistency in care amid supply challenges.